Braidwell’s Vor Biopharma VOR Stock Holding History

Braidwell’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Buy	573,104 +106,330	+23%	+$1.61M	0.39%	69
2026 Q1	$8.33M	Buy	+466,774	New	+$6.58M	0.28%	76

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Braidwell's VOR Position: Q2 2026 in Review

Braidwell increased its Vor Biopharma (VOR) stake by 23% in Q2 2026, buying an estimated $1.61M and bringing the position to 573,104 shares worth $10.6M. The position accounts for 0.39% of the portfolio, ranked #69.

Braidwell first reported a position in VOR in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Braidwell held 573,104 shares of Vor Biopharma worth $10.6M as of Q2 2026.
Braidwell bought 106,330 Vor Biopharma shares in Q2 2026, an estimated $1.61M.
Vor Biopharma made up 0.39% of Braidwell's portfolio in Q2 2026, its #69 holding.
Braidwell first reported a position in Vor Biopharma in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.